Impact of Drug Discontinuation
Bisphosphonates have a skeletal half-life of up to 10 years, taking 40–50 years to clear fully from bone. Discontinuation may improve clinical symptoms but rarely cures MRONJ, though it can lead to complete cure in osteoporosis patients. Prompt surgical intervention is recommended for osteoporosis patients once indicated. Monoclonal antibodies (e.g., Xgeva, Prolia / denosumab) have a half-life of ~28 days, with clinical effects subsiding by month 6. Sequestrum separation and spontaneous healing may occur before, at, or after the 6-month mark. If the underlying primary disease (osteoporosis or malignancy) progresses, restarting therapy may be necessary. Any alteration to drug regimens must be coordinated between the prescribing physician and the oral/maxillofacial surgeon.
Prevention
Given the difficulty of treatment, pre-therapy consultation with an oral surgeon or dentist is vital. Baseline dental health in these patients is often severely compromised. Prior to initiating antiresorptive therapy, non-restorable teeth should be extracted, bony edges smoothed (alveoloplasty), and mucosal wounds allowed to heal for at least four weeks. Marx recommends extracting even partially impacted third molars prior to antiresorptive therapy.
Tooth Extraction During Active Therapy
Tooth extraction is the leading cause of MRONJ. In patients on antiangiogenics or TKIs, extractions can proceed after a short drug holiday with minimal risk. Conversely, extractions during bisphosphonate or monoclonal antibody therapy carry a high risk of necrosis. A critical clinical error is retaining a severely compromised tooth; leaving a mobile tooth in place often leads to spontaneous exfoliation over pre-existing necrotic bone. Such teeth should be extracted using specific surgical protocols validated in clinical literature. Extraction is contraindicated in active, aggressive necrosis with ill-defined margins where teeth are mobile due to underlying bone loss rather than localized infection.
Alternative Therapies
Teriparatide can be utilized in osteoporosis patients with strong clinical results, though it is strictly contraindicated in oncology patients.
Provider Expertise
Unfortunately, expertise in managing MRONJ is not universal. Patients are frequently kept on prolonged conservative regimens, delaying timely surgical intervention and potential cure.
Surgical Prognosis
Osteoporosis patients achieve high surgical resolution rates. In oncology patients, the disease is more aggressive, and surgical treatment is not always successful. In some cases, necrosis progresses postoperatively, ultimately leading to pathological jaw fractures and structural loss.
